Results 11 to 20 of about 53,103 (125)

CMLLite: a design philosophy for CML [PDF]

, 2011
CMLLite is a collection of definitions and processes which provide strong and flexible validation for a document in Chemical Markup Language (CML). It consists of an updated CML schema (schema3), conventions specifying rules in both human and machine ...
Peter Murray-Rust, Townsend Joe A, Murray-Rust Peter, Joe A Townsend   +3 more
core   +13 more sources

The semantics of Chemical Markup Language (CML): dictionaries and conventions. [PDF]

, 2011
The semantic architecture of CML consists of conventions, dictionaries and units. The conventions conform to a top-level specification and each convention can constrain compliant documents through machine-processing (validation).
Townsend Joe A, Weerapong Phadungsukanan, Sam E Adams, Townsend JA, Thomas J, Joe A Townsend, Murray-Rust P, Thomas Jens, Phadungsukanan W, Peter Murray-Rust, Jens Thomas, Adams SE, Phadungsukanan Weerapong, Murray-Rust Peter, Adams Sam E   +14 more
core   +5 more sources

Abstracts

Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +4 more sources

Management of imatinib-resistant CML patients [PDF]

, 2007
Imatinib has had marked impact on outcomes in chronic myelogenous leukemia (CML) patients for all stages of the disease and is endorsed by international treatment guidelines as the first line option.
Dempke, Wolfram, Linke, Rolf
core   +1 more source

Empirical type I error and power in the secondary simulations comparing MR-cML-DP-S, CD-cML-DP-S and LHC-MR.

, 2022
Empirical type I error and power in the secondary simulations comparing MR-cML-DP-S, CD-cML-DP-S and LHC-MR.
Haoran Xue (1702663), Wei Pan (701)
core   +1 more source

Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34⁺ cells to imatinib [PDF]

, 2009
<p><b>Objective:</b> To investigate the interaction of imatinib mesylate (IM) with the clinically relevant adenosine triphosphate-binding cassette efflux transporter MDR1 (ABCB1) in cells from patients with chronic myeloid leukemia (CML)
Holyoake, T.L., Jordanides, N.E., Jorgensen, H.G., Hatziieremia, S., Mountford, J.C.   +4 more
core   +1 more source

Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters [PDF]

, 2009
Imatinib mesylate and nilotinib are highly effective at eradicating the majority of chronic myeloid leukemia (CML) cells; however, neither agent induces apoptosis of primitive CML CD34⁺ cells.
Holyoake, T.L., Davies, A., Jordanides, N.E., Giannoudis, A., Jorgensen, H.G., Harris, R.J., Hatziieremia, S., Mountford, J.C., Pirmohamed, M., Clark, R.E., Lucas, C.M.   +10 more
core   +2 more sources

BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia [PDF]

, 2012
MECOM oncogene expression correlates with chronic myeloid leukaemia (CML) progression. Here we show that the knockdown of MECOM (E) and MECOM (ME) isoforms reduces cell division at low cell density, inhibits colony-forming cells by 34% and moderately ...
Jørgensen, Heather G., Holyoake, T.L., Holyoake, T., Abed El Baky, Mohamed, Bartholomew, C., Melo, Junia V., Roy, P., Melo, J.V., Abed El Baky, M., Roy, S., Jørgensen, H., Jorgensen, H.G., Strathdee, G., Strathdee, Gordon, Melo, J., Roy, Swagata, Holyoake, Tessa L., Roy, Poornima, Bartholomew, Christopher   +18 more
core   +1 more source

Uptake of synthetic low density lipoprotein by leukemic stem cells — a potential stem cell targeted drug delivery strategy [PDF]

, 2010
Chronic Myeloid Leukemia (CML) stem/progenitor cells, which over-express Bcr-Abl, respond to imatinib by a reversible block in proliferation without significant apoptosis.
Jørgensen, Heather G., Jorgensen, Heather G., Tessa L. Holyoake, Heather G. Jørgensen, Scobie, Linda; id_orcid, Elliott, Moira A., Scobie, Linda, Crossan, Claire, Hatziieremia, Sophia, Zhou, Peixun; id_orcid, Elliott, Moira A, Sophia Hatziieremia, Michie, Alison M, Holyoake, Tessa L., Holyoake, Tessa L, Jørgensen, Heather G, Alison M. Michie, Halbert, Gavin W., Linda Scobie, Gavin W. Halbert, Moira A. Elliott, Claire Crossan, Michie, Alison M., Peixun Zhou, Halbert, Gavin W, Zhou, Peixun   +25 more
core   +1 more source

Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells [PDF]

, 2011
Chronic myeloid leukaemia (CML) is maintained by a rare population of tyrosine kinase inhibitor (TKI)-insensitive malignant stem cells. Our long-term aim is to find a BcrAbl-independent drug that can be combined with a TKI to improve overall disease ...
E K Allan, Holyoake, T.L., Jorgensen, H.G., A R Craig, T L Holyoake, Allan, E.K., Craig, A.R., H G Jørgensen   +7 more
core   +1 more source